Eli Lilly and Company (NYSE:LLY) Shares Acquired by Toronto Dominion Bank

Toronto Dominion Bank increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 393,065 shares of the company’s stock after acquiring an additional 976 shares during the period. Eli Lilly and Company comprises 0.6% of Toronto Dominion Bank’s investment portfolio, making the stock its 26th biggest position. Toronto Dominion Bank’s holdings in Eli Lilly and Company were worth $355,873,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Capital Planning LLC purchased a new position in Eli Lilly and Company in the 1st quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp acquired a new position in Eli Lilly and Company during the 1st quarter worth $6,916,000. M&G Plc purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $8,896,000. IPG Investment Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $351,000. Finally, HighPoint Advisor Group LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $9,878,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the transaction, the insider now directly owns 97,367,369 shares in the company, valued at $89,093,089,982.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 425,000 shares of company stock worth $394,455,351. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $924.89 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The business has a fifty day moving average of $894.11 and a 200-day moving average of $840.86. The stock has a market cap of $879.04 billion, a price-to-earnings ratio of 136.21, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the topic of a number of recent research reports. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Barclays boosted their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Bank of America lifted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Citigroup initiated coverage on Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price objective for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.